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E-mail addresses: Garth_Hall@uml.edu, dabize@gmAbnormal tau cleavage is prominent in the neuroﬁbrillary degeneration characteristic of Alzhei-
mer’s disease (AD) and related tauopathies. We recently showed that cleaved human tau is secreted
by speciﬁc mechanisms when overexpressed. Here we examined the effect of expressing N-terminal
and full length tau constructs in transiently and stably transfected neuronal lines. We show that
secreted tau exhibits a cleavage pattern similar to CSF-tau from human AD patients and that tau
secretion is speciﬁcally inhibited by the presence of the exon 2 insert. These results suggest that
tau secretion may play a hitherto unsuspected role in AD and related tauopathies.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Abnormal aggregation, phosphorylation and cleavage of the
microtubule-associated protein tau are central to the pathogenesis
of tau-associated neurodegenerative diseases (tauopathies) includ-
ing Alzheimer’s disease (AD), corticobasal degeneration (CBD) and
Pick’s disease. Since the presence of the alternatively spliced C-ter-
minal insert (exon 10, or e10) affects both tau:microtubule binding
and tau:tau aggregation [1], and is either overrepresented or
underrepresented in the neuroﬁbrillary aggregates of CBD and
Pick’s disease [2,3], it seems likely that e10 plays some role in dis-
ease pathogenesis [1,4]. However, there has hitherto been little
reason to suspect that the N-terminal alternatively spliced se-
quences encoded by exons 2 and 3 (e2 and e3) are involved in
pathological mechanisms leading either to tau aggregation or the
generation of cerebrospinal ﬂuid (CSF) tau. Recently, we found that
tau protein fragments can be secreted to the extracellular space in
an in situ tauopathy model via two distinct mechanisms, both of
which require the presence of an unknown element in the tau N-chemical Societies. Published by E
ticobasal degeneration; CSF,
system; MTBR, microtubule
, e3, e10, exons 2, 3 and 10
iological Sciences, University
MA 01854, USA. Fax: +1 978
ail.com (G.F. Hall).terminal domain [5]. These ﬁndings suggest that the predominance
of N-terminal tau fragments in the CSF of AD [6] might be ac-
counted for by the selective secretion of tau cleavage fragments
by living neurons rather than being exclusively due to neuronal
death and autolysis. However, the possible effect of N-terminal in-
serts on tau secretion was not tested in that study since we used
only tau isoforms (3R0N and 4R0N) lacking the e2 and e3 inserts
[5].
In order to clarify the roles played by either antecedent proteo-
lytic cleavage and/or the presence of e2–3 and other N-terminal
elements in modulating tau secretion, we assayed tau secretion
of N-terminal half constructs of e2/e3 tau (n591) and e2/e3+
tau (Dtau) from NB2a/d1 cells after transient expression and of
inducibly expressed full length e2 (4R0N tau isoform) and e2+
(4R1N and 3R1N tau isoforms, 4R1N/3R1N) tau isoforms from a
human derived tau-expressing cell line (M1C).
2. Materials and methods
2.1. Cell culture and selective induction of tau expression
We used M1C cells derived from human neuroblastoma (BE(2)-
M17D) cells (kindly provided by Dr. Ko – Mayo Clinic College of
Medicine, FL) to inducibly express wild type human tau, with
4R0N (four microtubule binding repeats and zero N-terminal
inserts) tau expression being induced by the tetracycline-offlsevier B.V. All rights reserved.
3086 W. Kim et al. / FEBS Letters 584 (2010) 3085–3088expression system (TetOff) and 3R1N/4R1N (three and four micro-
tubule binding repeats with e2 N-terminal insert) tau expression
being induced by the Ecdysone (Ecd) (Fig. 1A) [7]. M1C cells were
seeded in Dulbecco’s modiﬁed Eagle’s medium supplemented with
10% fetal bovine serum, G418 (400 lg/ml), hygromycin (100 lg/
ml), zeocin (100 lg/ml), tetracycline (2000 ng/ml).
Tau expression was induced by 1 ng/ml of tetracycline or
1 nmol/ml of Muristerone A (MA) for 10 days (Fig. 1A). Every
2 days, media were collected and fresh media were replaced to
M1C cells. At 10 days after tau induction, M1C cells were lysed in
Tris–NaCl (TN) buffer (50 mM Tris–HCl, pH 7.4, 150 mM NaCl, 1%
Triton-X, 10% glycerol, 2 mM EDTA, protease inhibitor cocktail
(Sigma)). Cell lysates were cleared by centrifugation at 10 000g
for 20 min. Total protein concentration of the supernatant was cal-
culated by BCA methods. To concentrate tau protein in medium,
Amicon Ultra 10K (Millipore, Billerica, MA) was used according
to the manufacturer’s protocol.
2.2. Transient transfection
The parent plasmids pRcCMV [5] and pcDNA/V5-DEST [8] were
used to transiently express e2/e3-negative (n591) and e2/e3+ (Dtau,
kindly provided by Dr. Lars Ittner) versions (respectively) of the tau
N-terminal (residues 1–255) inmouseneuroblastomaNB2a/d1 cells
(kindly provided byDr. Tom, SheaUniversity ofMassachusetts Low-
ell,MA) using Lipofectamine™2000 (Sigma) as previously described
[5]. Complete medium was replaced with serum-free medium 24 h
after transfection which was then collected, cleared and concen-
trated as described above after 24 h of incubation. NB2a/d1 cell ly-
sates were lysed in Tris–NaCl (TN) buffer and cleared. Supernatant
protein concentration was measured using BCA.
2.3. Immunoprecipitation
Protein G magnetic beads (New England Biolabs, Ipswich, MA)
were used for direct immunoprecipitation. 30 ll of Protein G mag-
netic beads were incubated with 1.5 ll of Tau12 (1 lg/ll) or 2 ll of
DM1A (1 lg/ml) with continuous mixing at room temperature for
20 min. Tau12 antibody–protein G bead complexes were washed
(PBS containing 0.1% Tween 20) and then incubated with 150 ll
of concentrated medium or 30 ll of cell lysates with agitation at
4 C overnight. Ab–tau complexes were then eluted with 60 ll of
0.2 M glycine and then neutralized with 10 ll of 1 M Tris–HCl
(pH 9.0).Fig. 1. (A) Either 4R0N tau (top) or both 4R1N/3R1N tau isoforms (center) were induce
Bottom: A schematic representation of the longest isoform tau (4R2N-441 residues) and
(4R0N) and Ecd (4R1N/3R1N) induction for 10 days, the overexpressed tau in M1C cells
3R1N tau expression in M1C cells was strongly induced compared to control () cells.
secreted, unlike low molecular weight Tau12 fragments. (C) Tau12 immunoprecipitates
fragments containing the N terminus. 4R0N tau was secreted much more efﬁciently to t
K9JA blots). Note that several K9JA/Tau12+ high molecular weight fragments (arrowhead
control for possible tau toxicity effects, M1C cells lysates and concentrated culture
immunoblotted with DM1A, showing that tubulin was absent from the culture medium2.4. Western blot and antibodies
Cell lysates, concentrated medium, and immunoprecipitated
samples were analyzed by Western blot. Electrophoresed samples
were transferred to polyvinyledene diﬂuoride membrane and incu-
bated with the following primary antibodies: Tau12 (1:10 000),
Tau46 (1:10 000), (a kind gift from Dr. Binder), K9JA (1:1000)
(DAKO), and DM1A (1:1000) (Sigma) (Fig. 1A). Goat anti-mouse
(1:10 000) or anti-rabbit (1:10 000) IgG, with Alkaline Phosphatase
conjugated second antibodies and BCIP/NBT substrate was used to
reveal immunostaining.
3. Results
We used induced tau expression from M1C cells (Fig. 1) and
transient transfection of NB2a/d1 cells (Fig. 2) to characterize tau
secretion and its dependence on unknown N-terminal elements
[5] in detail. Immunoprecipitation of secreted tau with the N-ter-
minal speciﬁc mAb Tau12 was used to analyze the generation
and secretion N-terminal-containing tau species from both in-
duced M1C cells and from NB2a/d1 cells that had been transiently
transfected with N-terminal (1–255) tau constructs. Results from
Immunoblot of M1C cell lysate and raw concentrated mediumwith
Tau12 and K9JA were used to quantitate the ratio of e2/e2+ tau
(Fig. 3). The relative amount of tau retained in cell lysates and se-
creted to media samples was analyzed by immunoblotting with
Tau12 (aa 9–18), K9JA (aa 243–441), and Tau46 (aa 428–441) [9].
3.1. Induction of the 4R0N tau isoform by TetOff induction in
transfected M1C cells results in proteolytic generation and selective
secretion of large and small tau fragments
Expression of 4R0N tau over 10 days was signiﬁcantly induced
(approximately 15 fold) by reducing tetracycline in the culture
medium to 1 ng/ml (Fig. 1A). Increased tau expression was accom-
panied by the generation of Tau12 and K9JA immunopositive
cleavage fragments. These were largely negative for Tau46 in
M1C cell lysates, which immunolabeled full length tau only
(Fig. 1B). Secreted tau (i.e. Tau12-immunoprecipitated tau from
medium) consisted of a select subset of these fragments that con-
tained the Tau12 site plus part of the C-terminal region (243–441)
recognized by the K9JA polyclonal (Fig. 1C). Tau46 failed to recog-
nize most of the secreted tau fragments. K9JA-positive, secreted
tau species occurred in two distinct groups of bands (22–35 kDad with reduced tetracycline (1 ng/ml) or via Muristeron A (1 nmol/ml) for 10 days.
the epitopes recognized with tau antibodies. (B) After tau induction (+) with TetOff
lysate was characterized using three different tau antibodies. Both 4R0N and 4R1N/
Note that most low molecular weight K9JA+ cleavage fragments (asterisk) are not
from concentrated media were analyzed by Western blot to identify secreted tau
he culture medium then 4R1N/3R1N tau (compare lanes 2 and 3 of both Tau12 and
s) and some low molecular weight fragments (double asterisks) are secreted. (D) To
d media from the experiments described above were immunoprecipitated and
.
Fig. 2. (A) N-terminal tau constructs (residues 1–255) encoding e2/e3 (n591 – top) or e2/e3+ (Dtau – bottom) were used to transiently transfect NB2a/d1 cells in tau
secretion assays. (B) Cell lysates and Tau12 immunoprecipitates of cell lysate and concentrated media samples from NB2a/d1 cells after transient expression of n591 andDtau
were immunoblotted with Tau12. To verify that Tau12 antibody recognized and immunoprecipitated N-terminal tau species with and without N-terminal inserts with
comparable efﬁciency, immunoblots of lysates from transfected NB2a/d1 cells were performed with (center lanes) and without (left lanes) Tau12-immunoprecipitation. The
presence of N-terminal inserts in the Dtau signiﬁcantly decreased the amount of secreted tau detected.
Fig. 3. The relative amount of extracellular (i.e. secreted) tau was signiﬁcantly increased with the absence of N-terminal insert region (e2) fromM1C inducible cells. (A) Tau12
and K9JA were used to determine the total tau in the cell lysate and the concentrated medium. Elevated levels of induced 4R0N and 4R1N/3R1N tau, via TetOff and Ecd system
respectively, were present in M1C cells. A higher amount of extracellular tau fragments from 4R0N tau, but not 4R1N/3R1N tau, was found in expressing cells. (B) Quantitative
densitometric analysis of the results shown in (A), showing the ratio of secreted versus retained 4R0N to 4R1N/3R1N tau isoforms. Values are represented as mean ± S.E. from
three experiments.
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uted very similarly within in each group (arrow heads, Fig. 1C),
suggesting that the lower MW group may have been generated
by the removal of an approximately 13 kDa (160 residue) frag-
ment from the C terminus, which would have to contain most or
all of the microtubule binding region (MTBR) (residues 257–367),
depending on the isoform. Levels of overexpressed tau sufﬁcient
to induce tau secretion at 10 days were not cytotoxic and did not
induce passive leakage of tubulin (or tau) to cultured media from
M1C cells, since tubulin was not detected when concentrated med-
ia were immunoprecipitated and then immunoblotted using the
anti-alpha tubulin antibody DM1A (Fig. 1D).
3.2. While a subset of 4R0N tau cleavage fragments are secreted
relatively efﬁciently from TetOff-induced M1C cells, Ecd induced 4R1N/
3R1N tau were mostly retained in cell lysates
While the levels of 4R0N and 4R1N/3R1N tau induced (by TetOff
and Ecd, respectively) seen in cell lysates was almost identical and
generated similar proteolytic cleavage patterns, much less extra-cellular 4R1N/3R1N than 4R0N tau was found in Tau12-immuno-
precipitates from medium (Fig. 1C), indicating that the presence
of the e2+ insert (residues 46–73) strongly and speciﬁcally inhib-
ited tau secretion either by blocking the secretion event itself or
by preventing the generation of secretable cleavage fragments.
3.3. Secretion of N-terminal tau fragments is strongly inhibited by the
presence of the e2 insert
In order to determine whether the inhibition of tau fragment
secretion from 4R1N/3R1N expressing M1C cells was a direct con-
sequence of the presence of the e2 N-terminal insert, we transfec-
ted NB2a/d1 mouse neuroblastoma cells with plasmids expressing
N-terminal tau constructs (residues 1–255) which either lacked
(n591) or contained (tau) both the e2 and e3 inserts (Fig. 2A). Cell
lysates and concentrated cultured media were prepared after 24 h
of expression, immunoprecipitated with Tau12, and blotted. While
n591 tau was secreted efﬁciently to the culture medium, Dtau was
not, even though Tau12 appeared to label Dtau more efﬁciently in
Tau12-immunoprecipitated lysates than did n591 (Fig. 2B). The re-
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above (Fig. 1C), and in addition, strongly suggests that the presence
of N-terminal insert region acts independently of the C-terminal
domain and by directly inhibiting secretion, rather than by pre-
venting the generation of secretable tau fragments.
3.4. Quantitation of e2+ mediated inhibition of tau secretion
For densitometric analysis of tau secretion using Image J, we
immunoblotted media samples without Tau12-immunoprecipita-
tion (Fig. 3). Quantitative analysis of M1C lysates and concentrated
media showed that while the ratio of e2/e2+ tau isoforms (4R0N
via TetOff of 4R1N/3R1N via Ecd induction) was almost 1:1
(1:0.97 ± 0.02, Mean ± S.E.; n = 3) in lysates, this ratio was in-
creased approximately 13-fold (1:12.71 ± 2.39) in the media sam-
ples, a highly signiﬁcant difference. We found a somewhat
smaller but still signiﬁcant relative decrease (from 1:1 to 1:3.26)
in the medium/lysate proportion of e2+ tau fragments when
K9JA was used.
4. Discussion
While the C-terminal alternatively spliced insert (e10) of tau,
which makes up the second MTBR, has been well studied and
has a relatively well deﬁned role in tau biology and pathobiology
[10], the functional signiﬁcance of N-terminal inserts (e2 and e3)
remains obscure, despite the fact that e2+ tau makes up over 60%
of the tau in the normal adult brain [11], and can be readily incor-
porated into insoluble neuroﬁbrillary deposits commonly found in
a number of neurodegenerative tauopathies [12]. In this study, we
found that (a) the secreted tau mainly consists of two groups of tau
fragments (molecular weights of 22–35 and 40–53 kDa, respec-
tively) that are immunopositive for mAbs to the N-terminal do-
main of tau, and resembles in size the tau fragments reported in
the CSF [13], and (b) the ability of tau to be secreted from viable
neurons [5] is speciﬁcally inhibited by the presence of e2.
Increased levels of total tau over age-matched controls have
been reported in the CSF of patients with a variety of traumatic
and neurodegenerative conditions, including AD, CBD, myotonic
dystrophy type 1, Parkinson’s disease-related dementia and after
ischemic and traumatic brain injury [6,13–17]. In each of these
conditions, CSF-tau was found to consist primarily of small (26–
33 kDa) and large (52–55 kDa) tau fragments that contain N-termi-
nal tau epitopes similar to those observed here [6,13,17]. Since the
calpains and or caspases activated post trauma and in tauopathies
have been shown to cleave tau at sites within the tau N-terminal
and on the extreme C-terminal which could yield such fragments
[18–21], it seems likely that the tau fragments observed in this
study were generated similarly, especially since tau overexpressed
above the levels needed to saturate microtubules is likely to be
more subject to calpain and caspase activity than normal microtu-
bule-bound tau [10,20,21]. This possibility is consistent with our
failure to observe signiﬁcant levels of secreted tau from stable cell
lines expressing tau at low levels (not shown), and raises the pos-
sibility that abnormal calpain or caspase activity in tauopathies
and/or post trauma could potentiate tau secretion in these
conditions.
Our recent ﬁnding that tau can be selectively secreted from live
neurons, together with observations that tau can be taken up into
neurons in culture [22], is toxic when applied extracellularly [23]
and can be propagated between neurons in the CNS [24] calls into
question the widespread assumption that the generation of CSF-
tau is invariably due to the passive tau release consequent to neu-
rodegeneration. The similarity of both secreted and CSF-tau species
to calpain and/or caspase cleavage fragments generated post trau-
ma and in association with tau induced neurodegeneration [18–21] are consistent with the possibility that the proteolytic cleavage
on either side of the tau MTBR seen in M1C cells in this study might
even potentiate the secretion of speciﬁc fragments of overexpres-
sed tau [5], which like the cleavage of ‘‘tauopathy” tau [20], is asso-
ciated with tau toxicity. Our results are therefore consistent with
the possibility that the secretion of speciﬁc cleavage fragments
may play a hitherto unsuspected role in the pathogenesis of neuro-
ﬁbrillary degenerative disease.Acknowledgements
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